Publicaciones en colaboración con investigadores/as de Instituto de Investigación Sanitaria Fundación para la Investigación del Hospital Clínico de Valencia (14)

2022

  1. Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer

    Science Advances, Vol. 8, Núm. 20

2021

  1. Circulating miR-30b-5p levels in plasma as a novel potential biomarker for early detection of breast cancer

    ESMO Open, Vol. 6, Núm. 1

  2. Identification of a two-microrna signature in plasma as a novel biomarker for very early diagnosis of breast cancer

    Cancers, Vol. 13, Núm. 11

2020

  1. Circulating mir-99a-5p expression in plasma: A potential biomarker for early diagnosis of breast cancer

    International Journal of Molecular Sciences, Vol. 21, Núm. 19, pp. 1-14

2019

  1. A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer

    Frontiers in Oncology, Vol. 9, Núm. APR

  2. A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients

    Clinical Epigenetics, Vol. 11, Núm. 1

  3. Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion

    European Journal of Cancer, Vol. 120, pp. 54-64

  4. The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors

    Scientific Reports, Vol. 9, Núm. 1

2017

  1. Defective cyclin B1 induction in trastuzumab-emtansine (T-DM1) acquired resistance in HER2-positive breast cancer

    Clinical Cancer Research, Vol. 23, Núm. 22, pp. 7006-7019

2015

  1. MicroRNA Profile in Response to Doxorubicin Treatment in Breast Cancer

    Journal of Cellular Biochemistry, Vol. 116, Núm. 9, pp. 2061-2073

2014

  1. Oxidative stress in susceptibility to breast cancer: Study in Spanish population

    BMC Cancer, Vol. 14, Núm. 1

  2. Retrospective analysis of the use of G-CSF and its impact on dose response for anthracycline plus taxane-based schedules in early breast cancer

    Clinical and Translational Oncology, Vol. 16, Núm. 9, pp. 814-822

2010

  1. ¿Qué avances nos ofrece la moderna Oncología?

    Anales (Reial Acadèmia de Medicina de la Comunitat Valenciana), Núm. 11

2005

  1. Development of a questionnaire to measure health-related quality of life (HRQoL) in patients with bone metastases (BOMET-QoL)

    Journal of Outcomes Research, Vol. 9, Núm. 15-27, pp. 15-27